The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Relvar Ellipta

184mcg/22 microgram(s) Powder for Inhalation

GlaxoSmithKline (Ireland) LimitedEU/1/13/886/004-006

Main Information

Trade NameRelvar Ellipta
Active SubstancesFluticasone furoate micronised
Vilanterol trifenatate micronised
Strength184mcg/22 microgram(s)
Dosage FormPowder for Inhalation
Licence HolderGlaxoSmithKline (Ireland) Limited
Licence NumberEU/1/13/886/004-006

Group Information

ATC CodeR03AK10 vilanterol and fluticasone furoate

Status

Authorised/WithdrawnAuthorised
Licence Issued13/11/2013
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back